Polymicrobial disease and inflammation in cystic fibrosis
Polymicrobial disease and inflammation in cystic fibrosis
批准号:
7388122
负责人:
Theodore Geh-Lu Liou
金额:
$18.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2010-03-31
关键词:
AcuteAntibioticsAreaBacteriaCaringCessation of lifeChronicClinicalClinical TrialsComplexCystic FibrosisDataDiseaseDisease ProgressionFailureFlareFoundationsFrequenciesFutureHost DefenseHumanImmune systemInfectionInflammationInflammatoryInflammatory ResponseLeadLifeLungLung diseasesMeasurementMeasuresMethodsMicrobial BiofilmsModelingMolecular BiologyNatureNumbersOrganismPatientsPatternPersonal SatisfactionPolymerase Chain ReactionPseudomonas aeruginosaRare DiseasesRelative (related person)Respiratory physiologyRiskSeveritiesShapesSourceSputumStagingStaphylococcus aureusTestingTimeTransplantationUnited Statesairway inflammationantimicrobialcostcystic fibrosis airwaycystic fibrosis patientscytokinedefense responseepidemiological modelimprovedmathematical modelmembernovelpatient registrypredictive modelingrapid techniqueresponsesuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This project seeks to understand the complex interactions between competing species of bacteria and the human immune system in the airways of patients with cystic fibrosis (CF). Our overall hypothesis is that complex interactions between bacterial species in the airways of patients with CF determine host defense responses and control the progression of airway disease. Our overall aim is to understand the interactions between Staphylococcus aureus and Pseudomonas aeruginosa, the most common bacteria infecting the lung in CF, and their interactions with the airway. These interactions appear to change the risk of death and vary the progression of the severe inflammation that causes airway damage and worsening lung function. Specifically, we will use epidemiologic and mathematical models to make precise testable predictions about the interactions between bacteria and the response of the airway. To provide data to modify and shape our models, we will use real-time quantitative PCR methods that we have newly developed to measure the numbers of each type of bacteria in the airway. We will perform measurements in a number of different clinical situations in order to understand how the burdens of these bacteria alter the course of disease. Using well established methods, we will measure inflammation as others have done before in CF, but, in contrast to past efforts, our focus will be to study how the intensity of inflammation varies as the burden of bacteria and the clinical circumstances vary. Our project will improve our understanding of how the two main species of bacteria in the CF airway alter disease course. Our new real-time quantitative PCR methods for rapid, precise and accurate measurement of bacteria will provide new clinical tools for assessing the extent of infection. These new tools will improve our ability to care for CF patients and other patients with infections by S. aureus and P. aeruginosa, for example, by improving our ability to apply antibiotics at the most favorable time to control flares of disease at the least effort and cost. Mathematically relating intensity of inflammation to the extent of infection will provide new opportunities for understanding the consequences of infection and the impact of treatments and may suggest new potential therapies and strategies for treating CF.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium.
提高西山区囊性纤维化联盟在囊性纤维化相关糖尿病的检测和管理方面的表现。
DOI:
10.1136/bmjdrc-2015-000183
发表时间:
2016
期刊:
BMJ open diabetes research & care
影响因子:
4.1
作者:
[Liou,TheodoreG, Jensen,JudithL, Allen,SarahE, Brayshaw,SaraJ, Brown,MarkA, Chatfield,Barbara, Koenig,Joni, McDonald,Catherine, Packer,KristynA, Peet,Kimberly, Radford,Peggy, Reineke,LindaM, Otsuka,Kim, Wagener,JeffreyS, Young,David, ]
通讯作者:
Carrier screening, incidence of cystic fibrosis, and difficult decisions.
携带者筛查、囊性纤维化的发生率和困难的决定。
DOI:
10.1001/jama.2009.1865
发表时间:
2009
期刊:
JAMA
影响因子:
--
作者:
[Liou,TheodoreG, Rubenstein,RonaldC]
通讯作者:
Rubenstein,RonaldC
DOI:
10.1016/j.toxlet.2012.10.016
发表时间:
2012-12-17
期刊:
Toxicology letters
影响因子:
3.5
作者:
[Tang M, Li Q, Xiao L, Li Y, Jensen JL, Liou TG, Zhou A]
通讯作者:
Zhou A
DOI:
10.1056/nejmc086289
发表时间:
2008
期刊:
The New England journal of medicine
影响因子:
--
作者:
[Liou,TheodoreG, Adler,FrederickR, Cahill,BarbaraC, Cox,DavidR]
通讯作者:
Cox,DavidR
Lung transplantation for cystic fibrosis.
肺移植治疗囊性纤维化。
DOI:
10.1097/01.mcp.0000245716.74385.3f
发表时间:
2006
期刊:
Current opinion in pulmonary medicine
影响因子:
3.3
作者:
[Liou,TheodoreG, Woo,MarlynS, Cahill,BarbaraC]
通讯作者:
Cahill,BarbaraC
共 6 条
Explanatory models of CF Survival, Infection and Intermediate Clinical Outcomes
-
批准号:9116284
-
项目类别:
-
资助金额:$33.79万
-
财政年份:2015
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS
-
批准号:7718484
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2008
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
CLINICAL TRIAL: AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS
-
批准号:7718524
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2008
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
CLINICAL TRIAL: CORRECTION OF STEATORRHEA IN PATIENS WITH CYSTIC FIBROSIS
-
批准号:7718529
-
项目类别:
-
资助金额:$1.96万
-
财政年份:2008
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
CLINICAL TRIAL: DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD
-
批准号:7718527
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2008
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS
-
批准号:7604981
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2007
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD CYSTIC FIBROSIS
-
批准号:7604984
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2007
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
Polymicrobial disease and inflammation in cystic fibrosis
-
批准号:7194860
-
项目类别:
-
资助金额:$22.43万
-
财政年份:2007
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
CORRECTION OF STEATORRHEA IN PATIENS WITH CYSTIC FIBROSIS
-
批准号:7604986
-
项目类别:
-
资助金额:$12.48万
-
财政年份:2007
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS
-
批准号:7604942
-
项目类别:
-
资助金额:$0.27万
-
财政年份:2007
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS
-
批准号:7376482
-
项目类别:
-
资助金额:$1.67万
-
财政年份:2006
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
CYSTIC FIBROSIS PATIENTS WITH LUNG DISEASE DUE TO P AERUGINOSA INFECTION
-
批准号:7201423
-
项目类别:
-
资助金额:$2.01万
-
财政年份:2005
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
Cystic fibrosis patients with lung disease
-
批准号:7044778
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2004
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
Diabetes therapy in CF subjects
-
批准号:7044808
-
项目类别:
-
资助金额:$0.17万
-
财政年份:2004
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP
-
批准号:6182393
-
项目类别:
-
资助金额:$12.39万
-
财政年份:1997
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP
-
批准号:2027173
-
项目类别:
-
资助金额:$8.75万
-
财政年份:1997
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP
-
批准号:6030390
-
项目类别:
-
资助金额:$12.39万
-
财政年份:1997
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP
-
批准号:2750282
-
项目类别:
-
资助金额:$8.75万
-
财政年份:1997
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP
-
批准号:6388394
-
项目类别:
-
资助金额:$12.39万
-
财政年份:1997
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
PMN CONTROL OF PROTEINASES IN A SEQUESTERED SPACE
-
批准号:2213774
-
项目类别:
-
资助金额:$3.53万
-
财政年份:1994
-
负责人:Theodore Geh-Lu Liou
-
依托单位:
海外基金